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ABSTRACT
BACKGROUND A 1-year follow-up, polymer-free metallic stent coated with biolimus-A9 followed by 1-month dual
antiplatelet therapy is safer and more effective than a bare-metal stent (BMS) for patients with high risk of bleeding.
OBJECTIVES This study analyzed 2-year outcomes to determine whether these beneﬁts are maintained.
METHODS In a prospective, multicenter, double-blind trial, we randomized 2,466 high bleeding risk patients to receive
a drug-coated stent (DCS) or a BMS followed by 1-month dual antiplatelet therapy. The primary safety endpoint was a
composite of cardiac death, myocardial infarction, or stent thrombosis. The primary efﬁcacy endpoint was clinically
driven target lesion revascularization.
RESULTS At 2 years, the primary safety endpoint had occurred in 147 DCS and 180 BMS patients (15.3%) (hazard ratio:
0.80; 95% conﬁdence interval: 0.64 to 0.99; p ¼ 0.039). Clinically driven target lesion revascularization occurred for 77
DCS and 136 BMS patients (12.0%) (hazard ratio: 0.54; 95% conﬁdence interval: 0.41 to 0.72; p<0.0001). Major bleeding
occurred in 8.9%of DCS and 9.2%of BMS patients (p¼0.95), and a coronary thrombotic event (myocardial infarction and/
or stent thrombosis) occurred in 8.2% of DCS and 10.6% of BMS patients (p¼ 0.045). One-year mortality was 27.1% for a
major bleed and 26.3% for a thrombotic event. At 2 years, multivariate correlates of major bleeding were age >75 years,
anemia, raised plasma creatinine, and planned long-term anticoagulation. Correlates of the primary safety endpoint were
age, anemia, congestive heart failure, multivessel disease, number of stents implanted, and use of a BMS rather than a DCS.
CONCLUSIONS Safety and efﬁcacy beneﬁts of DCS over BMS were maintained for 2 years in high bleeding risk
patients. Rates of major bleeding and coronary thrombotic events were no different and were associated with a
substantial and comparable mortality risk. (A Prospective Randomized Comparison of the BioFreedom Biolimus
A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding [LEADERS FREE];
NCT01623180) (J Am Coll Cardiol 2017;69:162–71) © 2017 The Authors. Published by Elsevier on behalf of the
American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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P atients at high bleeding risk (HBR) whorequire percutaneous coronary intervention(PCI) are a challenging group who need careful
evaluation of both their thrombotic and bleeding risks
when selecting a stent and determining duration and
intensity of antithrombotic management (1,2). Little
evidence exists to aid such decisions, because HBR
patients are mostly excluded from clinical trials of
antithrombotics and PCI (3–6). Until recently, the
perceived need for a very short course of dual anti-
platelet treatment (DAPT) often led operators to pre-
fer a bare-metal stent (BMS) to a drug-eluting stent
(DES) for such patients (7,8).
The LEADERS FREE (A Prospective Randomized
Comparison of the BioFreedom Biolimus A9 Drug
Coated Stent versus the Gazelle Bare Metal Stent in
Patients With High Risk of Bleeding) trial recently
showed that, together with a 1-month DAPT course, a
polymer-free metallic drug-coated stent (DCS) was
both safer and more effective than a BMS for patients
at high risk of bleeding who were followed for 1 year
(1). This DCS (BioFreedom, Biosensors Interventional
Technologies, Singapore) transfers biolimus A9, a
highly lipophilic sirolimus analog, into the vessel wall
over a 1-month period (9). This is in contrast to
currently available polymer-coated DES, which
generally release the drug over a period of several
months.
Limited encouraging 5-year data are available from
the ﬁrst-in-man evaluation of this DCS for 60 selected
patients treated with DAPT for 6 to 12 months (10).
For HBR patients with 1-month DAPT treatment,
further evidence is needed to assess whether the ﬁrst-
year beneﬁts of DCS over BMS are maintained in the
long term. Also, because of the unique features of the
LEADERS FREE design (i.e., unusual patient popula-
tion, very short DAPT time) together with the
observed high rate of major bleeding in both arms
after 1 year (1), it is important to evaluate the balance
of the 2-year risks and the baseline and pro-
cedure correlates of the primary safety
endpoint and of major bleeding events.
METHODS
PATIENTS. Patient selection and study design
of the LEADERS FREE trial have been des-
cribed previously (1,11). Inclusion required a
clinical indication for PCI together with 1 or
more HBR criteria: most frequently age 75 or
older, planned prolonged oral anticoagu-
lation, renal insufﬁciency, planned major
surgery, anemia or recent transfusion, and
cancer. Such patients were potential candi-
dates for a BMS instead of a DES, owing to their
perceived need for only 1 month of DAPT.
STUDY DEVICE AND PROCEDURE. The BioFreedom
polymer-free biolimus A9 coated stent, the con-
trol Gazelle BMS (Biosensors Europe, Morges,
Switzerland; and Biosensors Interventional Technol-
ogies), and the PCI procedure have been described
previously (1,11). A double-blind design was used. All
patients were to receive DAPT including both aspirin
(75 to 250 mg once daily) and a P2Y12 inhibitor (with
clopidogrel preferred) for 30 days followed by a single
antiplatelet agent thereafter (aspirin preferred). Pa-
tients requiring a vitamin K antagonist could be
treated either by triple therapy or a vitamin K
antagonist plus clopidogrel only during the ﬁrst 30
days. Patients had follow-up visits at 30 and 365 days
and were contacted either on site or by telephone at
60, 120, and 730 days. Ischemia testing and angio-
graphic evaluation during follow-up was left to the
investigator’s discretion.
STUDY DESIGN AND OVERSIGHT. A total of 2,466
patients from 68 sites were randomized to receive
either the BioFreedom DCS or the Gazelle BMS. The
study was sponsored by Biosensors Europe and con-
ducted by the Cardiovascular European Research
Center, an independent research organization paid by
SEE PAGE 172
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the sponsor. The respective roles of the executive
committee, the sponsor, Cardiovascular European
Research Center, and authors have remained un-
changed (1). The ﬁrst author, statisticians (J.G., S.C.),
and executive committee had unrestricted access to
the data and prepared all drafts of the manuscript;
they attest to the completeness and accuracy of all
data and to the adherence to study protocol. The
ethics committee at each site approved the trial, and
written informed consent was obtained from all
patients.
STUDY ENDPOINTS. The primary safety endpoint
was the cumulative incidence of a composite of car-
diac death, myocardial infarction, or deﬁnite or
probable stent thrombosis. The primary efﬁcacy
endpoint was the incidence of clinically driven target
lesion revascularization. Pre-speciﬁed secondary
endpoints included all-cause and cardiac mortality,
bleeding (Bleeding Academic Research Consortium
[BARC] deﬁnitions) (12), myocardial infarction (third
universal deﬁnition) (13), stent thrombosis (Academic
Research Consortium deﬁnitions) (14), and types of
coronary revascularization. A clinical events com-
mittee adjudicated all components of the primary
endpoints and all bleeding events, according to pre-
deﬁned criteria (1,11).
STATISTICAL ANALYSIS. All results are based on a
modiﬁed intention-to-treat analysis after exclusion of
34 patients who had no suitable lesion for PCI (1).
Continuous variables are presented as means, and
categorical data as counts and percentages. Time-to-
event analyses were performed using Kaplan-Meier
plots, log-rank tests, and proportional-hazard
models to estimate hazard ratios (HRs) and their
95% conﬁdence intervals (CIs). Proportional hazard
assumptions were checked using Schoenfeld re-
siduals. Patients were censored at death, withdrawal
from study, scheduled end of study, or 730 days post-
randomization, whichever occurred ﬁrst. We per-
formed sensitivity analyses using the Fine and
Gray method to estimate cumulative incidence of
events while adjusting for the competing risk of
mortality (15).
For major bleeding we used the BARC 3, 4, or 5
bleeding deﬁnition. To explore covariates associated
with major bleeding and the primary safety endpoint,
we performed multivariate analyses investigating the
potential inﬂuence of 32 baseline and procedural
variables (Online Table 1) by means of proportional
hazard models. We selected a ﬁnal model for each
outcome by using forward stepwise variable selection
on data with complete information on all covariates
and an inclusion criterion of p < 0.01. Based on the
trial results, we forced inclusion of BMS in the model
for the primary safety endpoint. We used multiple
imputations with chained equations to impute
missing data on covariates when calculating HR. We
used 10 imputed datasets and combined estimates
and SE across studies using the Rubin rules (16). To
calculate the HR for death following a thrombotic or
major bleeding event, follow-up of each patient was
divided into time spent before and after a major
bleeding or thrombotic event. The association be-
tween these events and subsequent mortality was
entered into a Cox-proportional hazards model as a
time-updated categorical variable that enters the
model on the day of the event (the methods in the
Online Appendix). HR therefore compare the hazard
of death after an event to the hazard before an event
(which includes the hazard in patients who do not
have an event during follow-up). We further broke
each patient’s follow-up after a thrombotic or major
bleeding event into 3 time intervals (0 to 7, 8 to 30,
and 31 to 365 days) based on similar analyses per-
formed in other studies (17).
HR for death were adjusted for correlates of
thrombotic or major bleeding events. Analyses were
performed with Stata Software (version 14.1, Stata
Corp., College Station, Texas) and SAS (version 9.3,
SAS Institute, Cary, North Carolina), and all p values
were calculated using 2-sided hypothesis tests.
RESULTS
PATIENTS. Of the 2,432 patients who underwent PCI,
2,386 (98.1%) were followed until death or 730 days
(Online Figure 1). Only 9 patients in the DCS arm and
3 in the BMS arm were lost to follow-up before 2
years. Patients were included based on pre-deﬁned
criteria of an increased bleeding risk, mainly
age $75 years (64.3%), prolonged oral anti-
coagulation (36.1%), renal failure (19.1%), planned
major surgery (16.4%), hemoglobin <11 g/l or recent
transfusion (15.6%), and cancer in the previous 3
years (9.8%). The DCS and BMS groups were well
matched with regard to baseline characteristics
(Online Table 2).
At 730 days, 78.8% of patients in the DCS group
and 76.8% in the BMS group were receiving single
antiplatelet therapy; 5.3% and 7.6%, respectively,
had DAPT; 15.8% and 15.6%, respectively, were tak-
ing no antiplatelet drug; and 37.7% and 38.0%,
respectively, were taking oral anticoagulants. Details
regarding antithrombotic treatment are given in
Online Table 3.
PRIMARY OUTCOMES AT 2 YEARS. We previously
reported outcomes using a 390-day time point (1).
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To facilitate comparisons between the ﬁrst and sec-
ond follow-up years, time points of 365 and 730 days
were used for 1 and 2 years in the present analysis.
Between 1 and 2 years, there were 53 new occurrences
of a primary safety endpoint in 37 DCS patients and
44 in 29 BMS patients. The primary safety outcomes
at 2 years occurred more frequently in the BMS than
in the DCS group (15.3% vs. 12.6%; HR: 0.80; 95% CI:
0.64 to 0.99; p ¼ 0.039) (Table 1, Central Illustration,
Figure 1).
Between 1 and 2 years, there were 24 new clinically
driven target lesion revascularizations (the primary
efﬁcacy endpoint) in 20 patients of the DCS group and
43 in 29 patients of the BMS group. Clinically driven
target lesion revascularization was required at least
once in 6.8% of DCS and 12.0% of BMS patients at 2
years (HR: 0.54; 95% CI: 0.41 to 0.72; p < 0.0001)
(Table 1, Central Illustration, Figure 1).
OTHER CLINICAL OUTCOMES. Other clinical out-
comes are summarized in Table 1. There were no
signiﬁcant differences in mortality between the DCS
and BMS groups in either all-cause mortality (13.1%
vs. 13.8%; HR: 0.94; 95% CI: 0.75 to 1.17; p ¼ 0.57) or
cardiac mortality (6.6% vs. 6.9%; HR: 0.94; 95% CI:
0.69 to 1.28; p ¼ 0.69) (Table 1). Between the ﬁrst and
second years of follow-up, 48 myocardial infarctions
occurred (25 in 20 patients of the DCS group, and 23 in
14 patients of the BMS group) and 2 very late deﬁnite
or probable stent thromboses (1 in the DCS group and
1 in the BMS group).
The incidence of coronary thrombotic events from
randomization to 2 years (deﬁned as any myocardial
infarction and/or deﬁnite or probable stent throm-
bosis) was signiﬁcantly lower with DCS than with BMS
(8.2% vs. 10.6%; p ¼ 0.045) (Table 1). Major bleeding
over 2 years occurred at a similar rate in both DCS and
TABLE 1 Clinical Outcomes at 1 and 2 Years With a DCS or BMS
1 Year 2 Years
DCS
(n ¼ 1,221)
BMS
(n ¼ 1,211) p Value
DCS
(n ¼ 1,221)
BMS
(n ¼ 1,211) p Value
Primary safety endpoint: cardiac
death, MI, or stent thrombosis
110 (9.2) 151 (12.7) 0.006 147 (12.6) 180 (15.3) 0.039
Primary efﬁcacy endpoint: clinically driven TLR 57 (4.9) 107 (9.3) <0.001 77 (6.8) 136 (12.0) <0.0001
Death
From any cause 91 (7.5) 105 (8.7) 0.27 156 (13.1) 164 (13.8) 0.57
From cardiac causes 49 (4.1) 61 (5.1) 0.23 76 (6.6) 80 (6.9) 0.69
MI*
Any 70 (5.9) 103 (8.7) 0.008 90 (7.4) 117 (10.1) 0.04
Q-wave infarction 6 (0.5) 7 (0.6) 0.77 6 (0.5) 10 (0.9) 0.31
Non–Q-wave infarction 55 (4.7) 78 (6.7) 0.04 67 (5.8) 86 (7.4) 0.09
Undetermined type 10 (0.8) 26 (2.2) 0.007 18 (1.6) 31 (2.7) 0.06
Stent thrombosis*
Deﬁnite or probable 24 (2.0) 26 (2.2) 0.75 25 (2.1) 27 (2.3) 0.76
Deﬁnite 16 (1.3) 17 (1.4) 0.84 17 (1.4) 17 (1.4) 0.98
Probable 8 (0.7) 9 (0.8) 0.80 8 (0.7) 10 (0.9) 0.63
Possible 25 (2.2) 26 (2.2) 0.85 36 (3.2) 35 (3.1) 0.95
Early deﬁnite or probable
(acute þ subacute)
12 (1.0) 15 (1.2) 0.55 — — —
Late deﬁnite or probable 13 (1.1) 11 (1.0) 0.70 — — —
Very late deﬁnite or probable — — — 1 (0.1) 1 (0.1) 0.99
Coronary thrombotic event*† 76 (6.4) 109 (9.3) 0.01 96 (8.2) 123 (10.6) 0.045
Bleeding*‡
BARC 1-5 213 (17.9) 225 (19.1) 0.50 258 (22.0) 255 (22.3) 0.89
BARC 2-5 165 (13.9) 173 (14.8) 0.61 204 (17.4) 206 (17.9) 0.83
BARC 3-5 85 (7.2) 85 (7.3) 0.96 105 (8.9) 105 (9.2) 0.95
Revascularization
Any TVR 65 (5.6) 119 (10.3) <0.001 91 (8.1) 151 (13.3) <0.0001
TVR by CABG 4 (0.3) 11 (1.0) 0.07 6 (0.5) 12 (1.1) 0.14
Any revascularization 94 (8.1) 134 (11.6) 0.003 129 (11.4) 180 (15.9) 0.001
Values are n (%). Percentages are Kaplan-Meier estimates at 365 (1 year) and 730 days (2 years). *Subcategories of MI, stent thrombosis, or bleeding are not mutually exclusive,
because patients could have >1 subtype of these events during follow-up. †Any MI and/or deﬁnite or probable stent thrombosis. ‡Bleeding was deﬁned according to the BARC
deﬁnitions. BARC type 0 indicates no bleeding, and BARC type 5 indicates fatal bleeding (11).
BARC ¼ Bleeding Academic Research Consortium; BMS ¼ bare-metal stent(s); CABG ¼ coronary artery bypass graft; DCS ¼ drug-coated stent(s); MI ¼myocardial infarction;
TLR ¼ target-lesion revascularization; TVR ¼ target-vessel revascularization.
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BMS groups (8.9% vs. 9.2%; p ¼ 0.95) (Central
Illustration). Pre-speciﬁed subgroup comparisons for
the primary efﬁcacy and safety endpoints are shown
in Online Figure 2. These analyses show a consistent
treatment effect across most subgroups. However,
interaction testing suggested heterogeneity of treat-
ment effect with regard to the primary safety
endpoint according to whether or not the patient
presented with an acute coronary syndrome, and
with regard to the primary efﬁcacy endpoint in pa-
tients with a CRUSADE (Can Rapid risk stratiﬁcation
of Unstable angina patients Suppress ADverse out-
comes with Early implementation of the ACC/AHA
guidelines) bleeding score >35. Both of these sub-
groups had already been identiﬁed at the 1-year
follow-up (1).
We identiﬁed 8 baseline and procedural charac-
teristics correlated with major bleeding and primary
safety endpoint events at 2 years: 4 were related
to the safety endpoint only (congestive heart failure,
multivessel disease, number of stents and stent type);
2 to bleeding events only (planned oral anti-
coagulation and raised plasma creatinine); and 2 to
both (age >75 years and low hemoglobin) (Table 2). Of
note, use of a BMS had a 33% relative increase in the
hazard for safety endpoint events (p ¼ 0.04)
compared with DCS after covariate adjustment.
The risks of all-cause death 1 year after a major
bleed and 1 year after a coronary thrombotic event
were 27.1% and 26.3%, respectively (Figure 2). Both
show a similar pattern with very marked excess
mortality risk within the ﬁrst week after such events—
especially for coronary thrombotic events—which
then attenuates over time (Table 3). A major bleed
remains associated with a signiﬁcant excess mortality
risk during 31 to 365 days after the event (adjusted
HR: 2.54; p < 0.001). These mortality patterns were
no different for both DCS and BMS groups, though the
former has a reduced risk of a coronary thrombotic
event (Table 1).
CENTRAL ILLUSTRATION HBR Patients After Polymer-Free DCS: Primary Safety Endpoint, Primary Efﬁcacy
Endpoint, Major Bleeding, and Individual Components of the Primary Safety Endpoint
Garot, P. et al. J Am Coll Cardiol. 2017;69(2):162–71.
The Kaplan-Meier time-to-event curves show the cumulative percentage of patients with the primary safety endpoint (a composite of cardiac death, myocardial
infarction, or stent thrombosis) (A), the primary efﬁcacy endpoint (clinically driven target-lesion revascularization) (B), major bleeding (C), and the 3 components of
the safety endpoint (D to F). BMS ¼ bare-metal stent(s); DCS ¼ drug-coated stent(s); HBR ¼ high bleeding risk.
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DISCUSSION
For HBR patients receiving a 1-month course of DAPT,
2-year follow-up in the LEADERS FREE trial demon-
strates, for both efﬁcacy and safety, the sustained su-
periority of the BioFreedom polymer-free biolimus
A9-coated stent (DCS) compared with a similar BMS.
In this patient population, both the risks of
major bleeding and of a composite of cardiac death,
myocardial infarction, or stent thrombosis were high.
Both types of events were associated with several
baseline and procedure characteristics, and when 2 of
the components of the primary safety endpoint
(myocardial infarction and/or stent thrombosis) were
analyzed for their associated post-event 1-year all-
cause mortality, this was high—26.3%—and compara-
ble to that observed after major bleeding (27.1%).
Encouragingly for the DCS, no “catch-up” of target
lesion revascularization was observed beyond 1 year.
This is in keeping with studies of a polymer-free stent
as well as a rapid-elution permanent polymer DES
(18,19) and different from what has been seen with
ﬁrst generation DES (20). It is plausible that biolimus
A9 is particularly well suited to rapid delivery into the
vessel wall because of its marked lipophilicity (9). The
low incidence of very late stent thrombosis in both
trial arms (<0.1%) suggests that absence of any
polymer on the DCS may contribute to its long-term
safety despite the very short DAPT and compares
favorably with stent thrombosis rates for polymer-
coated DES, especially in this high risk population
(21–26).
These data conﬁrm the good long-term results of
DCS observed in a previous study (10). However, HBR
patients continue to suffer a high incidence of
adverse events beyond the ﬁrst year, most likely due
to advanced age, major comorbidities, and possibly
because of only partial revascularization in some
patients (multivessel disease was reported in 62% of
patients, but multivessel index revascularization was
done in only 22%) (1). Two-year mortality was 13.1%
for DCS versus 13.8% for BMS patients. This is higher
than observed in all-comer trials and again points to
the impact of comorbid conditions (23,26–29).
The ZEUS (Zotarolimus-Eluting Endeavor Sprint
Stent in Uncertain DES Candidates) trial randomized
TABLE 2 Multivariate Correlates of Primary Safety Endpoint and
Major Bleeding
HR (95% CI) p Value
Primary safety endpoint*
Age >75 yrs 1.56 (1.23–1.97) <0.001
Hemoglobin (per 1 mmol/l <9) 1.32 (1.19–1.46) <0.001
Congestive heart failure at baseline 1.61 (1.23–2.11) 0.001
Multivessel disease at baseline† 1.66 (1.27–2.18) <0.001
Number of stents implanted
(per additional stent)
1.13 (1.04–1.23) 0.005
BMS 1.28 (1.03–1.59) 0.027
Major bleeding event‡
Age >75 yrs 1.52 (1.13–2.06) 0.006
Hemoglobin (per 1 mmol/l <9) 1.73 (1.52–1.96) <0.001
Serum creatinine >150 mmol/l 1.58 (1.10–2.27) 0.012
Planned OAC use post-PCI 2.01 (1.51–2.68) <0.001
*Primary safety endpoint: composite of cardiac death, myocardial infarction, and
deﬁnite/probable stent thrombosis. †Multivessel disease includes patients with
site-reported 2- or 3-vessel and/or left main disease. ‡BARC bleeding score 3 to 5.
BMS ¼ bare-metal stent(s); CI ¼ conﬁdence interval; HR ¼ hazard ratio; OAC ¼
oral anticoagulants; PCI ¼ percutaneous coronary intervention.
FIGURE 1 Landmark Analysis at 1 Year for the Primary Safety and Primary Efﬁcacy Endpoints
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The Kaplan Meier time-to-event curves show the cumulative percentage of patients who reached the primary safety endpoint (left) and the primary efﬁcacy endpoint
(right) for the ﬁrst time between 365 and 730 days.
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1,606 patients considered uncertain DES candidates
to either a ﬁrst-generation rapid-elution zotarolimus
DES with a biocompatible permanent polymer or a
thin-strut BMS (30). Among these patients, 52% had
HBR, and their median DAPT duration was 30 days.
The overall trial found better safety and efﬁcacy for
the DES, even more pronounced for HBR patients
with substantial reductions in myocardial infarction
and target vessel revascularization and a stent
thrombosis rate of 2.6% versus 6.2% for DES and BMS,
respectively (2,30). Two other randomized trials
evaluated this rapid-elution zotarolimus-eluting DES
in low bleeding risk patients and concluded that a
3-month course of DAPT was as safe and effective as a
prolonged course of DAPT, but both were somewhat
underpowered (5,6). The larger DAPT trial enrolled
9,961 low to medium bleeding risk patients after im-
plantation of several slow-eluting DES and an un-
eventful ﬁrst 12 months’ period and evaluated
prolonged DAPT. Rates of myocardial infarction and
stent thrombosis were signiﬁcantly lower with 30
than with 12 months’ DAPT, but at the cost of an in-
crease in bleeding (31).
The recent NORSTENT (Norwegian Coronary Stent
Trial) randomized 9,013 patients to either a
contemporary DES or a thin-strut BMS, and it found
that with a 9-month DAPT course in both arms and
after a 6-year follow-up, both stent types were
equivalent for safety (cardiac death or myocardial
infarction), whereas DES were superior in terms of
need for repeat revascularization and a lower rate of
stent thrombosis (32). Because both the DAPT
duration and the patients’ risk proﬁles were very
different from those of LEADERS FREE, we believe
that both trials complement rather than contradict
each other. BMS design is unlikely to be a major
factor, because the thin strut BMS used in
NORSTENT were very similar to those used in ZEUS,
where active stents were also both safer and more
effective than BMS in HBR patients treated with a
short course of DAPT (2,30).
Interest in shortening DAPT when needed is now
considerable, and there are at least 9 randomized
trials currently planned or ongoing to evaluate DAPT
regimens of 3 months or less after coronary stenting.
Some use stents with rapid drug transfer to the vessel
wall, a logical feature when very short DAPT appears
desirable, and others use stents coated with either a
permanent or biodegradable polymer that delivers
the antiproliferative drug over several months.
Whether such strategies are safe remains to be
demonstrated (33).
One important ﬁnding in our trial is that both
bleeding and coronary thrombotic event rates
(myocardial infarction and/or stent thrombosis) are
high and similar in HBR patients. Although this bal-
ance has already been described for all-comer pa-
tients (34), both types of events are clearly more
frequent in HBR patients. In the present trial, 8.2% of
patients suffered a coronary thrombotic event
(myocardial infarction and/or stent thrombosis) and
8.9% suffered a major bleeding event at 2 years in the
DCS group, whereas these events occurred in 10.6%
for thrombotic and 9.2% for bleeding events in the
BMS group. In the PARIS (Patterns of Non-Adherence
to Anti-Platelet Regimen in Stented Patients) registry
that analyzed 4,190 patients after coronary stenting,
the majority of whom were maintained on DAPT for at
least 1 year, coronary thrombotic events occurred in
3.8% and major BARC bleeding (BARC 3 or 5) in 3.3%
(34–37). This difference is again most probably due to
the more advanced age and greater comorbidity of
HBR patients, compared with an all-comer popula-
tion. Of interest is the fact that the ratio of thrombotic
to bleeding events at 2 years was very similar in both
trials (0.92 for the DCS arm and 1.15 for the BMS arm
in LEADERS FREE, and 1.15 in PARIS).
The risk of ensuing mortality is also high, espe-
cially soon after the event. Of note is the persistently
high excess mortality out to 1 year after a major bleed.
These ﬁndings are similar to those of ACUITY
(Acute Catheterization and Urgent Intervention
Triage Strategy Trial) (17), a trial focused on patients
presenting with acute coronary syndrome, but the
adjusted HR for mortality associated with major
bleeding and thrombotic events were markedly
FIGURE 2 1-Year Mortality Following a Major Bleed or a Coronary Thrombotic Event
30
25
20
15
10
5
0
0 90 180 270 365
Days Since Event
Pa
tie
nt
s D
ea
d 
(%
)
Major bleed Thrombotic event
Kaplan-Meier time-to-event curves show the cumulative percentage of patients who died
within 1 year following a major bleed or a thrombotic event throughout the 2-year study
period.
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higher in LEADERS FREE, again suggesting that such
events are of greater consequence for HBR than for
younger patients with less comorbidity. The trade-off
for any change in antithrombotic management may
be ﬁnely balanced: a longer DAPT course might
decrease thrombotic complications, but, most likely
at the price of an increased risk of major bleeding
(35,36). LEADERS FREE was designed to compare a
new stent to a BMS using the accepted standard of 1
month DAPT in HBR patients, but the optimal dura-
tion of DAPT still remains to be determined in this
high-risk population.
Among characteristics associated with either
bleeding or the primary safety endpoint (Table 2),
anemia, like age, was related to both. This stresses
the limitations of using certain correlates to assess
either bleeding or thrombotic risks in isolation when
deciding about the intensity and duration of DAPT. As
previously reported, anemia is a powerful prognostic
indicator after PCI, more so for bleeding than for
thrombosis in our series, and it has historically
received insufﬁcient attention (38–40). For avoidance
of bleeding, the need for long-term oral anti-
coagulation should always be carefully reassessed
after PCI (40). Renal insufﬁciency was correlated only
with bleeding in our series, but it has also been re-
ported as a predictor of thrombotic complications by
others (34,37). It could either be that its thrombotic
risk is of comparatively lesser importance for HBR
patients who by deﬁnition often have other comorbid
conditions, or that patients with the most severe
renal dysfunction are already captured by their
associated anemia.
STUDY LIMITATIONS. First, results are not directly
applicable to non-HBR patients who are likely to
tolerate longer courses of DAPT. For non-HBR pa-
tients, a 6- to 12-month course, perhaps longer, is
associated with beneﬁt (7,8,31) and a minimum of
12 months remains the guideline when such patients
present with ACS (7,40). Second, our results
cannot be generalized to other DES or DCS with
different drugs or slower elution kinetics. Further
evidence is needed, and those trials are currently
underway.
CONCLUSIONS
The safety and efﬁcacy beneﬁts of a polymer-free
biolimus A9-eluting stent versus a BMS together
with a short 1-month DAPT course were maintained
during 2 years of follow-up. The persistently high
incidence of both bleeding and coronary thrombotic
events in HBR patients needs wider recognition and
deserves our full attention in future trials of antith-
rombotic therapy.
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TABLE 3 1-Year Mortality Following a Major Bleed or Coronary Thrombotic Event
Patients
With Event Deaths
Person-Time
at Risk (yrs)
Rate
(per Person-Year
at Risk)
Adjusted HR Versus No
Event (95% CI)
First year after event
Thrombotic event
No event or before event 2,432 256 4,137.3 0.06 1.00 (reference)
0–365 days 219 64 257.3 0.25 4.43 (3.24–6.04)
Major bleeding
No event or before event 2,432 255 4,153.5 0.06 1.00 (reference)
0–365 days 210 65 241.1 0.27 3.43 (2.49 to 4.74)
Time since event
Thrombotic event
No event or before event 2,432 256 4,137.3 0.06 1.00 (reference)
0–7 days 219 24 3.9 6.22 77.96 (49.29–123.30)
8–30 days 195 11 11.8 0.93 11.51 (6.19–21.40)
31–365 days 183 29 241.6 0.12 1.53 (0.93–2.53)
Major bleeding
No event or before event 2,432 255 4,153.5 0.06 1.00 (reference)
0–7 days 210 16 3.8 4.2 36.11 (20.82–62.64)
8–30 days 192 3 11.9 0.25 2.41 (0.76–7.65)
31–365 days 186 46 225.4 0.2 2.36 (1.60–3.48)
Abbreviations as in Table 2.
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